Pharmaceutical and a host of other companies will be expected to voluntarily pay into a new fund covering their use of genetic data, the UN COP16 biodiversity summit agreed, but countries failed to reach a wider agreement on global finance for nature after talks ran overtime and were suspended.
1 per cent of revenue would have meant a $67mn payment last year from Switzerland’s Roche, the biggest non-US pharma company by sales, alone. Expert observers to the negotiations noted that the use of the word “should”, rather than “shall”, meant that these would essentially be voluntary contributions by companies, rather than the mandatory levy that some countries had been pushing for.
이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오: